Antithrombotic therapy in cancer

Journal of Clinical Oncology

Volumn 23, Issue 10, 2005, Pages 2119-2120

  Lemoine, Nicholas R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 7A; FILAMIN A; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 2; THROMBOPLASTIN; FIBRINOLYTIC AGENT;

CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; EDITORIAL; HUMAN; LUNG EMBOLISM; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; VEIN THROMBOSIS; BLOOD CLOTTING; CANCER INVASION; DRUG ADMINISTRATION; NEOPLASM; NOTE; PHYSIOLOGY; PROGNOSIS; SURVIVAL;

ANTICOAGULANTS; BLOOD COAGULATION; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 17144416517     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.10.975     Document Type: Editorial

References (18)

1. Green D, Hull RD, Brant R, et al: Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 339: 1476, 1992
2. Siragusa S, Cosmi B, Piovella F, et al: Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 100:269-277, 1996
3. Gould MK, Dembitzer AD, Doyle RL, et al: Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A meta-analysis of randomized, controlled trials. Ann Intern Med 130:800-809, 1999
4. Kakkar AK, Levine MN, Kadziola Z, et al: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22:1944-1948, 2004
5. Altinbas M, Coskun HS, Er O, et al: A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2:1266-1271, 2004
6. Lee AYY, Rickles FR, Julian JA, et al: A randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23:2123-2129, 2005
7. Klerk CPW, Smorenburg SM, Otten HM, et al: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23:2130-2135, 2005
8. Kakkar AK, Lemoine NR, Scully MF, et al: Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 82:1101-1104, 1995
9. Ott I, Fischer EG, Miyagi Y, et al: A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 140:1241-1253, 1998
10. Taniguchi T, Kakkar AK, Tuddenham EG, et al: Enhanced expression of urokinase receptor induced through the tissue factor-factor Vlla pathway in human pancreatic cancer. Cancer Res 58:4461-4467, 1998
11. Kakkar AK, Chinswangwatanakul V, Tebbutt S, et al: A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Haemostasis 28:1-6, 1998
12. Wojtukiewicz MZ, Rucinska M, Zacharski LR, et al: Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost 86:1416-1420, 2001
13. Belting M, Dorrell MI, Sandgren S, et al: Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 10:502-509, 2004
14. Mousa SA, Mohamed S: Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 92:627-633, 2004
15. Mousa SA, Mohamed S: Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: Anti-cancer efficacy. Oncol Rep 12:683-688, 2004
16. Da Silva MS, Horton JA, Wijelath JM, et al: Heparin modulates integrin-mediated cellular adhesion: Specificity of interactions with alpha and beta integrin subunits. Cell Commun Adhes 10:59-67, 2003
17. Yoshitomi Y, Nakanishi H, Kusano Y, et al: Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett 207:165-174, 2004
18. Muramatsu H, Zou P, Suzuki H, et al: α4β1- and α6β1-integrins are functional receptors for midkine, a heparin-binding growth factor. J Cell Sci 117:5405-5415, 2004